# Richard E. Pratley

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/richard-e-pratley/

## Facts

| Field | Value |
| --- | --- |
| Citations | 64,069 |
| Field | Diabetes Treatment and Management |
| h-index | 122 |
| i10-index | 365 |
| Last Known Institution | Translational Research Institute |
| OpenAlex ID | https://openalex.org/A5059098934 |
| ORCID iD | 0000-0002-2912-1389 |
| Works | 709 |

## Researcher papers

Showing 12 of 20.

- [Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects](https://scholariq.org/papers/leptin-levels-in-human-and-rodent-measurement-of-plasma-leptin-and-ob-rna-in/)
- [Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia](https://scholariq.org/papers/hypoadiponectinemia-in-obesity-and-type-2-diabetes-close-association-with/)
- [2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>](https://scholariq.org/papers/2-classification-and-diagnosis-of-diabetes-i-standards-of-care-in-diabetes-2023/)
- [The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus](https://scholariq.org/papers/the-natural-history-of-insulin-secretory-dysfunction-and-insulin-resistance-in/)
- [2. Diagnosis and Classification of Diabetes:<i>Standards of Care in Diabetes—2024</i>](https://scholariq.org/papers/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes-2024/)
- [Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials](https://scholariq.org/papers/cardiovascular-mortality-and-kidney-outcomes-with-glp-1-receptor-agonists-in-2/)
- [Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes](https://scholariq.org/papers/cardiovascular-outcomes-with-ertugliflozin-in-type-2-diabetes/)
- [Impaired Fasting Glucose and Impaired Glucose Tolerance](https://scholariq.org/papers/impaired-fasting-glucose-and-impaired-glucose-tolerance/)
- [Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes](https://scholariq.org/papers/association-of-sglt2-inhibitors-with-cardiovascular-and-kidney-outcomes-in/)
- [Diabetes in Older Adults](https://scholariq.org/papers/diabetes-in-older-adults/)
- [Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial](https://scholariq.org/papers/semaglutide-versus-dulaglutide-once-weekly-in-patients-with-type-2-diabetes/)
- [Vitamin D Supplementation and Prevention of Type 2 Diabetes](https://scholariq.org/papers/vitamin-d-supplementation-and-prevention-of-type-2-diabetes/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)

## Researcher university

- [Translational Research Institute](https://scholariq.org/institutions/translational-research-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.